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Immature dendritic cells (DCs) resident in bovine spleens represent a distinct CD11a CD11c CD13
CD172 CD205 population compared to those circulating in peripheral blood or trafficking via afferent
lymph. Upon cytokine-induced maturation, splenic DCs both efficiently present antigen in the stimulation of
allogeneic lymphocyte proliferation and recall antigen-specific responses.
Dendritic cells (DCs) initiate adaptive immune responses by
taking up an antigen and, following their maturation and mi-
gration to T-lymphocyte-rich zones, presenting the antigen to
T cells in the context of the major histocompatibility complex
(MHC) and costimulatory molecules (2, 31). Specific vaccine
targeting of DCs has been shown to enhance priming and to
convert nonimmunogenic tumor antigens into effective immu-
nogens that induce protective immunity (3). Using DNA vac-
cine vectors expressing the Flt3 ligand and granulocyte-mac-
rophage colony-stimulating factor (GM-CSF), along with a
microbial antigen, we have shown that increased recruitment
of DCs to the skin enhances the efficacy of DNA vaccines in
cattle and that the CD4 T-lymphocyte responses are signifi-
cantly amplified (23). However, there is strong evidence that
priming, expansion, and maintenance of memory T lympho-
cytes and trafficking of these T cells upon challenge can be
organ specific and are greatly influenced by the site of initial
antigen presentation (6, 17, 21). Importantly, DC lineages dif-
fer among organs, and thus contemporary approaches that
modify vaccine vectors to enhance the transfection and expres-
sion of vaccine antigens in organ-specific DCs may require
different targeting strategies.
While DC lineages have been best studied in mice and hu-
mans, there is clear evidence for different lineages in cattle
with functional differences in their abilities to stimulate CD4
and CD8 T cell responses (12, 28). However, these studies
have not examined the spleen, the critical organ for priming
and expansion of the immune response against blood-borne
parasites (4, 8, 26, 27). Consistent with the critical role of the
spleen in initiating protective immunity, splenectomy markedly
delays the development of antigen-specific immune responses
following infection with the blood parasites Anaplasma and
Babesia spp., resulting in severe disease and, usually, death (16,
18). With a long-term goal of developing novel vaccines that
will effectively induce immune responses that control these
important hemoparasitic diseases of cattle, we are focused on
improving our understanding of how immune responses are
initiated and expanded in the spleen. The objective of the
present study was to characterize splenic DCs and determine if
they are phenotypically distinct from peripheral blood DCs
and previously described bovine DC lineages obtained from
afferent lymph (9, 12, 13).
Spleens were surgically removed from healthy male Holstein
calves and, rinsed in phosphate-buffered saline (PBS) contain-
ing 20% (vol/vol) acid citrate dextrose (ACD) with 100 U
penicillin and 100 g streptomycin per ml. The spleen was
mechanically disrupted using a tissue grinder, and cells were
obtained by passing small fragments through a 100-m-pore-
size nylon cell strainer (BD Falcon). Spleen cells were centri-
fuged at 430  g and resuspended in four volumes of Tris-
buffered 0.87% ammonium chloride for 10 min. Remaining
cells were washed in PBS-ACD, suspended in fetal bovine
serum containing 10% dimethyl sulfoxide, and cryopreserved
in liquid nitrogen. Peripheral blood mononuclear cells
(PBMC) were isolated from the same calves and cryopreserved
in liquid nitrogen using the same procedure as used for the
spleen cells. B lymphocytes and monocytes were isolated from
PBMC by positive selection using, respectively, the monoclonal
antibodies (MAbs) BAQ44A and CAM66A (Table 1). Follow-
ing 30 min of incubation at 4°C with the appropriate MAb, the
cells were washed three times in PBS, incubated with goat
anti-murine immunoglobulin M (IgM) microbeads (Milteny
Biotec), and positively selected using a magnetic field. Macro-
phages were derived by culture of adherent PBMC in complete
RPMI 1640 medium on 100-mm petri dishes (Becton Dickin-
son) at 37°C in 5% CO2 for 7 days. Accutase (Innovative Cell
Technologies) was used to collect adherent cells.
The strategy used to identify splenic DC populations was to
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select cells expressing MHC class II molecules and then to
remove those other cell subsets that also express MHC class II
molecules: monocytes, macrophages, B lymphocytes,  T
lymphocytes,  T lymphocytes, and NK cells (30). The re-
maining MHC class II molecule-expressing population, puta-
tive DCs, was then analyzed morphologically for characteristic
dendrite formation, phenotypically for cell surface markers
expressed by other bovine DC lineages, and functionally for
the ability to present antigen and stimulate lymphocyte re-
sponses. This approach was necessary as, in the absence of
prior studies of bovine splenic DCs, there are no lineage-
specific markers; this approach was also necessary to avoid the
bias that all bovine DCs, regardless of lineage, share a common
cell surface marker. For sorting, spleen cells and PBMC were
incubated with two sets of isotype-specific primary MAbs: (i)
IgM MAbs specific for bovine CD2 (expressed on  T lym-
phocytes and NK cells), B lymphocytes,  T lymphocytes
(-chain specific), and CD14 and (ii) IgG2a MAb specific for
bovine MHC class II (HLA-DR orthologue) (Table 1). After
incubation for 30 min on ice, cells were washed three times in
cold PBS by centrifugation at 430  g and then incubated with
the secondary antibodies, phycoerythrin (PE)-conjugated goat
anti-murine IgM and fluorescein isothiocyanate-conjugated
goat anti-murine IgG2a, for 15 min on ice. Cells were washed
twice in cold PBS, and then putative DCs that were MHC class
II positive but negative for CD2, CD14, B-lymphocyte, and 
T-lymphocyte markers were gated and sorted using a Vantage
fluorescence-activated cell sorter (Becton Dickinson) (Fig. 1).
Sorted putative splenic DCs were then cultured in complete
RPMI 1640 medium supplemented with 200 ng/ml of recom-
binant bovine interleukin 4 (IL-4) (10, 24), 100 ng/ml recom-
binant bovine GM-CSF (23, 24), 100 ng/ml recombinant bo-
vine Flt3 ligand (22, 24), and 10 g/ml recombinant bovine
CD40 ligand (rbCD40L). To obtain bovine CD40L, a DNA
construct encoding the extracellular domain of bovine CD40L
(CD40L-ED) linked in-frame with the sequence encoding the
CD5 secretory signal sequence (7) was generated in the ex-
pression vector VR-1055 (Vical). A bovine CD40L-ED-spe-
cific forward primer (5 ATACTGCAGATGGTGTATCTTC
ACAGACGATTG 3) and a bovine CD40L reverse primer (5
ATAGGATCCTCACTTATCGTCATCGTCCTTGTAGTCCC
CTGGACCAGGTCCGAGTTTGAGTAAGCCAAATGA
3) were used to PCR amplify the CD40L-ED open reading
frame from cDNA generated from bovine T lymphocytes stim-
ulated with ionomycin and phorbol myristic acetate as previ-
ously described (11). The reverse primer was extended to in-
clude complementary sequence (in bold) of the codons
encoding the FLAG tag (amino acid sequence, DYKDDDDK)
(20) and also introduced a BamHI restriction site (in italics) at
FIG. 1. Isolation of bovine splenic DCs. MHC class II cells that
were negative for the expression of CD2, CD14, and B- and  T-
lymphocyte markers (Lineage) were gated (circled population) for
isolation by sorting.
FIG. 2. Bioassay of recombinant bovine CD40L. The biological
activity of rbCD40L was tested by its ability to stimulate B-lymphocyte
proliferation in the presence of 200 ng/ml recombinant bovine IL-4
(10, 24). Means 	 standard deviations of results from triplicate wells
are shown. TdR, thymidine.
TABLE 1. Monoclonal antibodies used for phenotypic
analysis and cell sorting
Antibody Isotype Specificity Sourcea
H34A IgG2b MHC class II VMRD
TH22A IgG2a MHC class II VMRD
BAQ44 IgM B cell VMRD
GB25A IgG1 B cell VMRD
CAM66A IgM CD14 VMRD
CAM36A IgG1 CD14 VMRD
CACT31A IgM CD2 VMRD
BAQ95A IgG1 CD2 VMRD
MM1A IgG1 CD3 VMRD
CACT61A IgM  T-cell receptor  chain VMRD
CACTB81A IgG1  T-cell receptor  chain VMRD
GB21A IgG2b  T-cell receptor  chain VMRD
IL-11A IgG2a CD4 VMRD
CC30 IgG1 CD4 IAH
CACT80C IgG1 CD8 VMRD
CC13 IgG1 CD1 Serotec
HUH73A IgG1 CD11a VMRD
MM12A IgG1 CD11b VMRD
BAQ153A IgM CD11c VMRD
DH59B IgG1 CD172a VMRD
GC42A IgG1 CD45RO VMRD
ILA116 IgG3 CD45RO IAH
CC81 IgG1 CD13 IAH
CC98 IgG2b CD205 IAH
IL-A159 IgG1 CD80 IAH/EU
IL-A190 IgG1 CD86 IAH/EU
AKS1 IgG1 CD335 (NK cells 
30) NVS
a VMRD, Veterinary Medical Research and Development, Pullman, WA;
IAH, Institute for Animal Health, Compton, England, United Kingdom (pro-
vided by Chris Howard); EU, Edinburgh University, Edinburgh, Scotland,
United Kingdom (provided by N. MacHugh); NVS, Norwegian School of Vet-
erinary Science, Oslo, Norway (provided by A. K. Storset).
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FIG. 3. Morphology of bovine splenic DCs. Immature DCs immediately after sorting (A) and mature DCs after 72 h of culture at magnifications
of 300 (B) and 600 (C) are shown.
FIG. 4. Comparison of the abilities of different antigen-presenting cells to stimulate an allogeneic lymphocyte response and correlation with activation
phenotype. (A) Stimulation of allogeneic lymphocyte proliferation by increasing numbers of mature splenic or peripheral blood DCs, macrophages, B
lymphocytes, or monocytes. Means 	 standard deviations of results from triplicate wells are shown. The response induced by monocytes was identical
to that of B lymphocytes and thus is not shown. (B) MHC class II, CD80, and CD86 surface molecule expression on mature splenic and peripheral blood
DCs and macrophages (black profile). The background of secondary antibody binding is indicated by the gray profile. TdR, thymidine.
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the 3 end of the PCR product, designated cd40ledflag. The
CD5 secretory signal sequence was added at the 5 end of
cd40ledflag by PCR using two overlapping primers (5 ACCT
TGTACCTGCTGGGGATGCTGGTCGCTTCCTGCCTCG
GACTGCAGATGGTGTATCTTCACAGACG 3 and 5 AT
AGATATCACCATGCCCATGGGGTCTCTGCAACCGCT
GGCCACCTTGTACCTGCTGGGGATGCTG 3), and the
second primer introduced an EcoRV restriction site (in bold)
at the 5 end of the PCR product. The resultant construct,
designated cd5cd40ledflag, was EcoRV-BamHI digested and
subcloned into the VR-1055 eukaryotic expression vector to
generate a construct designated CD40L-ED. rbCD40L was
expressed as FLAG-tagged protein in 293 Free-Style cells
(Invitrogen) and affinity purified using Anti-FLAG M2-aga-
rose gel (Sigma) as previously described (24). Purified pro-
tein was then tested for biological activity with B lympho-
cytes positively selected with magnetic beads from PBMC
using a modified protocol of a previous study (29). Briefly, B
lymphocytes (2  105 cells/well) were incubated in triplicate
with 200 ng/ml recombinant bovine IL-4 (10, 24) either
alone or in combination with rbCD40L in a concentration
range between 0.1 ng to 10 g per ml. Cells were incubated
for 72 h at 37°C with 5% CO2, and proliferation was mea-
sured by radiolabeling with 0.25 Ci of [3H]thymidine over
the last 18 h of culture. Cells were collected using an auto-
mated cell harvester (Tomtec), and incorporated [3H]thy-
midine was counted with a liquid scintillation counter. The
stimulation of significant dose-dependent proliferation of
B lymphocytes (1, 19) demonstrated that the recombinant
cytokine was biologically active (Fig. 2).
Microscopic examination of the putative splenic DCs imme-
diately after sorting revealed a rounded appearance (Fig. 3A).
Small dendrites appeared following overnight culture, and nu-
merous long cytoplasmic veils and aggregates, typical of fully
mature DCs, developed within 72 h (Fig. 3B and C). To ex-
amine the ability of these mature DCs to present antigen and
stimulate T cells, two assays were performed. The first was an
allogeneic T-cell stimulation in which sorted splenic DCs, DCs
sorted from PBMC, B lymphocytes, macrophages, and mono-
cytes (obtained from calves with the MHC class II DRB3
*0101/*1201 alleles) were irradiated and individually cultured
with 1  105 lymphocytes (obtained from a calf with MHC
class II DRB3 *4501/*3001 alleles) in round-bottom 96-well
plates in 100 l of complete RPMI 1640 medium for 96 h at
37°C in 5% CO2. Proliferation was measured by adding 0.25
Ci [3H]thymidine for the final 18 h of cultivation, followed
by cell harvesting and liquid scintillation counting as de-
scribed above. DCs sorted from the spleen and from periph-
eral blood induced significantly higher (P  0.05) prolifer-
ative responses of allogeneic lymphocytes than did purified
macrophages, monocytes, or B lymphocytes (Fig. 4A). The
magnitude of lymphocyte proliferation was proportional to
the number of DCs added (Fig. 4A) and the comparative
effectiveness of the DCs as antigen-presenting cells associ-
ated with the surface expression of MHC class II, CD80, and
CD86 molecules (Fig. 4B).
The second functional assay measured the ability of DCs to
stimulate antigen-specific recall responses. A short-term T-
lymphocyte cell line was established from a calf (MHC class II
DRB3 *1201/*1201) immunized with Anaplasma marginale
MSP2 protein (5). Briefly, CD8- and  T-cell-depleted PBMC
were stimulated with MSP2 for 1 week, followed by a 1-week
rest as previously described (23). The specific MSP2 peptide
P16-7, previously shown to be presented by the MHC class II
DRB3 *1201 allele (25), or a negative control peptide, P1,
were added to autologous splenic DCs or macrophages as
antigen-presenting cells and cultured with 3  104 cells of the
T-lymphocyte cell line. After 72 h, cells were pulsed with
[3H]thymidine and harvested as described above. Both splenic
DCs and macrophages presented antigen and induced antigen-
specific CD4 T-cell recall responses, with significantly higher
responses (P  0.05) stimulated by DCs when either 300 or
3,000 antigen-presenting cells were used (Fig. 5).
To identify the surface phenotype of these splenic DCs,
monoclonal antibodies recognizing a series of both activation
markers and surface markers previously identified on bovine
afferent lymph DCs were used in multicolor flow cytometry.
DCs (MHCII CD2 B cell  CD14) derived from either
peripheral blood or spleen were incubated with MAbs specific
for each of the following cell surface markers: CD1, CD11a,
CD11b, CD11c, CD13, CD45RO, CD80, CD86, CD172a, and
CD205 (Table 1). After incubation for 30 min on ice, cells were
washed three times in complete RPMI 1640 medium contain-
ing 0.02% sodium azide by centrifugation at 300  g. Fluores-
cein isothiocyanate-, PE-, allophycocyanin-, or PE-Cy5-conju-
gated isotype-specific goat anti-mouse antibodies were used as
secondary antibodies (Caltag Laboratories and Southern Bio-
tech). After incubation for 15 min on ice, labeled cells were
washed twice in cold PBS and fixed in 1% formaldehyde. A
minimum of 80,000 labeled cells were analyzed by flow cytom-
etry using a FACSort (Becton Dickinson). Splenic and periph-
eral blood DCs were clearly distinct from the B lymphocytes,
monocytes, and macrophages, being negative for these lineage-
specific markers (data not shown). The splenic DCs were phe-
notypically distinct from both the peripheral blood DCs and
the two previously described types of afferent lymph DCs (Ta-
ble 2). Between DCs derived from peripheral blood versus
spleen, the major surface phenotypic difference was the high
level of CD13 (14) expression on the splenic DCs (Fig. 6). The
expression of this marker, which is a type II transmembrane
FIG. 5. Comparison of the abilities of mature splenic DCs and
macrophages to induce an antigen-dependent T-lymphocyte recall re-
sponse. Specific MSP2 peptide antigen (P16-7) or a control peptide
(P1) was added to either splenic DCs or macrophages for presentation
to an MSP2-specific T-cell line (25). Means 	 standard deviations of
results from triplicate wells are shown.
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protein, was not linked to differential activation status, as both
sets of DCs revealed very low or no expression of CD80 or
CD86 (Table 2). Splenic DCs also displayed expression levels
of CD11b, CD11c, and CD205 different from those of periph-
eral blood DCs (Fig. 6). CD205, a type I cell surface glyco-
protein, is expressed on different DC lineages in mice (15) and
has been used as a lineage marker to isolate DCs from the
large-sized bovine afferent lymph veiled cells (9, 12, 13). Ex-
amination of total gated CD205 cells in the bovine spleen
included both B (CD21) and T lymphocytes (CD3) (data
not shown). Thus, although the splenic DCs uniformly ex-
pressed CD205, CD205 cannot be used as a specific DC
marker or as a specific targeting molecule for vaccine delivery.
Splenic DCs were also distinct from the two well-described
subsets of afferent lymph DCs (12, 13) based on multiple dis-
criminatory surface markers (Table 2). Splenic DCs did not
express CD45RO or CD1, which are expressed on both subsets
of afferent lymph DCs. Uncultured splenic DCs also exhibited
an immature phenotype, as indicated by the low level of
CD80/86 expression, while the higher level of expression on
the afferent lymph DCs is indicative of a more mature pheno-
type.
Maturation of splenic DCs using IL-4, the Flt3 ligand, GM-
CSF, and CD40L induced strong expression of both CD80 and
CD86 (Fig. 4B) concomitantly with a complete loss of CD13
(data not shown). This mature phenotype was linked to the
capacity of the DCs to present antigen effectively (Fig. 4A and
B). Comparison with identically cultured peripheral blood DCs
revealed differences in expression of all three CD11 molecules:
mature splenic DCs had higher levels of CD11a and CD11c
expression but lower levels of CD11b than mature peripheral
blood DCs. Thus, the two populations of DCs retain distinct
cell surface phenotypes following maturation.
In the present study we have identified a distinct CD13 DC
population in bovine spleens that is phenotypically unique
compared to other peripheral blood, lymph node, and afferent
lymph DCs and confirmed its effectiveness in antigen presen-
tation in both the allogeneic T-cell stimulation reaction and
the induction of T-cell recall responses. Unlike the two subsets
FIG. 6. Splenic and peripheral blood DCs display distinct cell surface phenotypes. Uncultured DCs were analyzed by flow cytometry. Levels
of expression of CD13, CD11b, CD11c, and CD205 are indicated by the solid line. The background of secondary antibody binding is indicated by
the light gray dotted lines.












MHC class II    
CD1b    
CD2    
CD4    
CD8    
CD11a    
CD11b 	   
CD11c   	 
CD13    
CD21     or 
CD45RO    
CD80 	 	  
CD86    
CD172a    
CD205    
a Intensities of monoclonal antibody binding are indicated as  (negative), 	
(weak),  (positive), or  (strongly positive), according to the conventions of
Howard and Hope (13). In this study, these symbols are defined as follows: ,
60% of cells were positive; , 15 to 59% of cells were positive; 	, 15% were
positive; and , cells were negative.
b Splenic and peripheral blood DCs were analyzed as uncultured cells using
three-color flow cytometry.
c Data are from references 12 and 13. Uncultured cells were examined.
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of bovine afferent lymph DCs, which differ in surface pheno-
type, including in the expression of CD11a, CD13, and
CD172a, there was no definitive evidence of multiple splenic
DC subsets when the cells were examined either prior to or
following activation. However, minor subsets not detected in
normal spleens from healthy animals may well be identified if
there is specific expansion or activation by delivery of antigens,
including the blood-borne pathogens Anaplasma and Babesia,
to the spleen. Determining how splenic DCs are activated and
migrate following the initial encounter with the pathogen and
how priming in the spleen affects T-cell trafficking represent
the next challenges for better understanding immunity against
these important pathogens.
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